VIMIZIM

Peak

elosulfase alfa

BioMarin Pharmaceutical
BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 2014
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

Pharmacologic Class:

Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme

Company
BioMarin Pharmaceutical
BioMarin Pharmaceutical
NOVATO, CA
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers